Class Action Cites Zetia & Vytorin

          NEWARK (CN) – In a shareholder’s class action that neatly summarizes complaints about Schering-Plough Corp.’s sales of its cholesterol drugs Zetia and Vytorin, the Arkansas Teacher Retirement System claims: “Sixteen months after completion of a study showing that its two most profitable drugs had no greater health benefit than far cheaper generic competitors – and may even be harmful – Schering sold over $4 billion of its own securities to the investing without disclosing the results of the study. This lack of disclosure violated the securities laws.”




     The complaint continues: “It took the Company another five months to disclose some of the study results and when it did, Schering’s stock dropped precipitously and investors were harmed. Ten weeks after that initial disclosure, Schering disclosed the study results in their entirety, which caused the stock to drop even further.
     “Defendant Schering manufactures and markets two anti-cholesterol drugs called Zetia and Vytorin. Vytorin is a combination of Zetia and Zocor – in generic form, simvastatin – and is jointly manufactured and marketed with Merck & Co., Inc. Total sales of Zetia and Vytorin were $3.9 billion in 2006 and $5.2 billion in 2007. These drugs are Schering’s most profitable, accounting for 70 percent of its profits, by one estimate.”
     This is not the first such class action against Schering-Plough. Courthouse News reports it because its first six pages contain a clear and concise summary of the allegations, and the history of the medical trials that Schering allegedly failed to disclose.
     Plaintiffs are represented by James Cecchi with Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein of Roseland, N.J.

%d bloggers like this: